A Clinical Trial of Chemotherapy With Lobaplatin and 5-FU in Recurrent Local or Distant Advanced NPC.

Inclusion Criteria: * NPC diagnosed by pathology, with measurable lesions and imaging results, such as MRI and CT. Patients with no other lesions but bone metastasis are excluded. * Recurrent locally or distant advanced NPC (rT3-4N0-3M0-1) * ECOG 0 or 1 * Expected survival ≥ 1 year * Without dysfunction of heart, lung, liver, kidney and hematopoiesis * Patients are voluntary and signed informed consent * No other anti-tumor treatment (including steroid) Exclusion Criteria: * Allergy history to platinum * Use of 5-FU in last 6 months * Had major surgery in last 4 weeks, or the wound has not completely healed * Toxicity from previous treatment is still ≥CTC AE grade 3 * History of other carcinoma in the past 5 years, except for treated carcinoma in situ of cervix, as well as basal cell carcinoma or squamous cell carcinoma of the skin * Dysfunction of heart * Bleeding ≥CTC AE grade 3 * Use of anticoagulant or vitamin K antagonists, except for small dose of aspirin and warfarin for prevention * Patients participated in clinical trials of other drugs within last 4 weeks * Mental illness